clinical-trial-design

Overview

clinical-trial-design covers the architecture of interventional clinical studies: choosing the phase and design (parallel, crossover, factorial, adaptive), defining endpoints, randomizing and blinding, sizing the sample, and planning analyses that regulators and journals accept. A trial's credibility is fixed at the design stage — no analysis rescues a trial that measured the wrong thing in the wrong population.

When to use

• Choosing trial phase and design for a new intervention.
• Defining primary/secondary endpoints and estimands.
• Randomization schemes: simple, blocked, stratified, minimization.
• Blinding: who, how, and when it's impossible (surgical/behavioral trials).
• Sample-size calculation and interim analyses with alpha spending.
• Adaptive designs: group sequential, sample-size re-estimation, platform trials.
• Writing protocols and CONSORT-compliant reports.

Core concepts

• Phases. Phase I: safety/tolerability (often healthy volunteers, dose escalation). Phase II: preliminary efficacy + dose finding. Phase III: confirmatory efficacy vs standard of care (large, randomized, the basis for approval). Phase IV: post-marketing surveillance. Skipping phases is occasionally justified, never casual.
• Estimands (ICH E9 R1). Define precisely what treatment effect you estimate: population, treatment conditions, endpoint, handling of intercurrent events (discontinuation, rescue medication), summary measure. "Intention-to-treat" is an estimand choice, not a default virtue — state it.
• Endpoints. Primary: one (or a co-primary pair), clinically meaningful, measured reliably. Surrogate endpoints (biomarkers) are acceptable only when validated — lowering a lab value is not the same as helping patients. Patient-reported outcomes belong in most modern trials.
• Randomization. Blocked randomization keeps arms balanced over time; stratification balances key prognostic factors (site, disease severity); minimization for many strata. Use a central, concealed system — envelope randomization is a known failure point.
• Blinding. Double-blind where possible; when impossible (surgery, psychotherapy), blind the outcome assessors and statisticians at minimum, and use objective endpoints. Assess blinding success — failed blinding with subjective endpoints is a major bias source.
• Sample size. Powered on the primary endpoint's minimum clinically important difference, with realistic variance and dropout inflation (10-20%). Underpowered trials are unethical — they expose patients to risk for uninterpretable results.
• Interim analyses. Group-sequential designs with alpha-spending functions (O'Brien-Fleming, Pocock) allow early stopping for efficacy or futility. Unplanned peeking at the data inflates Type I error — all interim looks must be prespecified with a data monitoring committee.
• Design variants. Crossover (each patient gets both treatments — efficient, but only for stable chronic conditions without carryover); factorial (two interventions at once, tests interaction); non-inferiority (margin must be clinically justified, not statistically convenient); platform/adaptive trials (shared infrastructure, dropping arms — efficient but operationally demanding).

Practical workflow

1. PICO. Population, Intervention, Comparator, Outcome — one sentence that the whole trial hangs on. If the comparator isn't the real clinical alternative, the trial answers the wrong question.
2. Estimand and endpoints. Primary endpoint, intercurrent-event strategy, analysis population. Register on ClinicalTrials.gov before enrollment.
3. Design choice. Parallel-group default; crossover/factorial/adaptive only with justification.
4. Size it. Power 80-90% on the MCID; inflate for dropout; document assumptions.
5. Randomize and blind. Central system, stratified blocks; blinding plan with fallback for unblindable interventions.
6. Monitor. Independent DMC, prespecified interim analyses, safety stopping rules.
7. Analyze as planned. ITT primary; per-protocol as sensitivity; handle missing data with prespecified methods (not last-observation-carried-forward).
8. Report CONSORT. Flow diagram, baseline table, primary result with effect size + CI, harms by arm. Publish regardless of outcome — publication bias kills evidence synthesis.

Common pitfalls

• Surrogate primary endpoints without validation (the drug works on the biomarker, not the patient).
• Underpowered trials ("exploratory" as an excuse for n=30 confirmatory claims).
• Unplanned interim looks inflating false positives.
• Per-protocol presented as primary (breaks randomization).
• Non-inferiority margins chosen to guarantee success.
• Comparator that's a straw man (placebo where an active standard exists).
• Selective outcome reporting — publishing a different primary endpoint than registered.